Aim: Non-invasive assessment of changes in liver fibrosis is still an unmet medical need in the era of antiviral therapy. Therefore, we explore whether chitinase 3-like 1 (CHI3L1), a serum marker of liver fibrosis, can be used as a non-invasive surrogate marker of fibrosis change during treatment.
INTRODUCTION

I
MPROVEMENT OF LIVER fibrosis is an important goal for chronic hepatitis B (CHB) patients receiving antiviral therapy, therefore, dynamic assessment of liver fibrosis changes is important. 1, 2 Although liver biopsy is still the gold standard to assess liver fibrosis, its invasive nature prevents it from wide use. There is an unmet clinical need to develop a non-invasive and quantitative measurement for liver fibrosis change during treatment.
Chitinase 3-like 1 (CHI3L1) is a member of the chitinase-like protein family. 3 Previous studies have shown that CHI3L1 levels are significantly correlated with stages of fibrosis in CHB patients. 4 However, whether changes in CHI3L1 levels can be used to monitor fibrosis changes in CHB patients during antiviral therapy has not been assessed.
In this study, we correlated the serum CHI3L1 levels with the collagen proportionate area (CPA) and liver stiffness measurement (LSM) in CHB patients who received antiviral therapy. We wanted to evaluate the change in CHI3L1 levels pre-and post-therapy as a practical and non-invasive method to monitor fibrosis changes.
METHODS
Study cohort
C LINICAL DATA AND serum samples were from patients of the "Regression Study" (ClinicalTrials. gov: NCT01938781 and NCT01938820). A total of 131 CHB patients were included in the final analysis. Inclusion criteria were: men or women aged 18 to 65 years; hepatitis B surface antigen positivity for at least 6 months and treatment-naive before screening; serum hepatitis B virus (HBV)-DNA load >20 000 IU/mL in hepatitis B envelope antigen (HBeAg)-positive patients or 2000 IU/mL in HBeAg-negative patients at baseline (prior to antiviral therapy). Exclusion criteria included: co-infection with hepatitis C or HIV; presence of chronic liver disease caused by other etiologies; decompensated cirrhosis; α-fetoprotein >100 ng/mL; creatinine >1.5 times the upper limit of normal; malignant tumors; severe disease of heart, lung, kidney, brain, blood system, or other organs; and pregnant or lactating women.
All patients received entecavir (ETV)-based treatment after initial evaluation of liver fibrosis by biopsy, and a second liver biopsy was carried out after 78 weeks of treatment.
Collection of clinical data and LSM
Demographic data were collected at baseline (0 week), and clinical laboratory tests were carried out at baseline and at 26-week intervals including blood cell counts, HBV-DNA level, serological markers of HBV, liver biochemical parameters, α-fetoprotein, prothrombin time, liver ultrasonography, and LSM.
Transient elastography (FibroScan; Echosens, Paris, France) was undertaken on the right lobe of the liver through the right intercostal according to previously described methods. 5 The obtained value (LSM) was reported as the median of 10 successful measurements. The results were expressed in kPa. The values with at least 10 valid measurements, with success rates ≥60% and with the interquartile range over the median ratio less than 30%, were considered reliable, and were included in the analysis.
Histological assessment
Liver tissues were formalin fixed and paraffin embedded. The specimens were then stained with hematoxylin-eosin, reticulin, and Masson trichrome and independently evaluated by two experienced hepatopathologists. Necroinflammation was assessed by the modified histology activity index grading system (scale, 0-18) and fibrosis was staged with the Ishak fibrosis scores (scale, 0-6).
Assessment of CPA
The CPA was measured on unstained liver sections by a second-harmonic generation (SHG)/two-photon-excited fluorescence (TPEF) technology-based microscope (Genesis200; HistoIndex, Singapore). The specimen was scanned to generate multiple adjacent images under a 20× objective and the images stitched together to form a whole slide picture (Fig. S1 ). The SHG microscope was used to visualize collagen and TPEF was used to identify cell structures. After normalizing the SHG signals by the area percentage of TPEF signals, the CPA was computed. 6, 7 Serum CHI3L1 measurement
The concentrations of serum CHI3L1 were measured using CHI3L1 ELISA kits (Hangzhou Proprium Biotech, Hangzhou, China) according to the manufacturer's instructions. 4 A standard curve was generated using the four-parameter logistic regression model. The correlation coefficients of CHI3L1 ELISA kits were >0.9900. The detection limit was 0.035 ng/mL. The measurement for our study passed the quality control with the values of the low and high concentration quality control samples at 0.14-0.15 ng/mL and 0.57-0.66 ng/mL, respectively, within the ranges for the low concen-tration (0.12-0.18 ng/mL) and high concentration (0.48-0.72 ng/mL) values of quality control. The intra-assay coefficients of the variations of the low and high concentration samples were 4.5% and 4.1%, respectively.
Statistical analysis
Normally distributed continuous variables were expressed as means with standard deviations and compared by Student's t-test. Non-normally distributed variables were reported as medians with interquartile ranges and compared by the Wilcoxon matched-pairs test and the Kruskal-Wallis test. Categorical variables were compared using the χ 2 -test and Fisher's exact test. Correlations between parameters were undertaken using Spearman's rank test. The performance of biomarkers to identify liver fibrosis was assessed by receiver operating characteristic (ROC) curve analysis. Linear regression analyses were used to determine the associated factors with pre-and post-treatment CHI3L1 levels. A P-value <0.05 was considered statistically significant. Statistical analyses were undertaken using SPSS version 20.0 (IBM, Chicago, IL, USA).
The study protocol was approved by the Ethics Committee of Beijing Friendship Hospital (Beijing, China). The study was carried out in accordance with the ethical guidelines of the 1975 Declaration of Helsinki (2008 revision). Written informed consent was provided by all patients.
RESULTS
Baseline characteristics and virologic and histological changes after 78 weeks of treatment A TOTAL OF 131 patients were included in the final analysis ( Fig. 1) . Most of the patients were men (78%), the mean age was 39 years, and 71% of patients were HBeAg-positive. The median level of baseline serum HBV-DNA was 6.7 log IU/mL. After 78 weeks of treatment, 71% patients (93/131) achieved virologic and biochemical responses, the HBV-DNA was undetectable (virologic response) in 85% of patients, and alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels declined to the normal range (biochemical response) in 83% of patients. Histological assessment also showed improvement in necroinflammation and fibrosis ( Table 1) . The median inflammation score decreased from 7 to 4 (P < 0.001) and the proportion of patients with pronounced necroinflammation (≥10) decreased from 18.3% (24/131) at baseline to 2.3% (3/131) at week 78 (Fig. 2a) . Fibrosis scores decreased in 40% of patients (53/131), and the proportion of patients with significant fibrosis and more (Ishak ≥2) decreased from 95.4% (125/131) to 86.2% (113/131) (Fig. 2b) . The serum CHI3L1 level also declined significantly compared with that at baseline (median, 87.8 vs. 69.6 ng/mL, P < 0.001) (Fig. 2c) . There was no significant difference in CPA, CHI3L1, or LSM between patients with biochemical and virologic response and non-responders (Table S1 ).
Baseline CHI3L1 levels correlated with CPA and LSM At baseline, the median levels of CHI3L1 were high, which increased with fibrosis stage and were highest in cirrhosis patients (Fig. S2) . The correlation analysis found positive correlations between serum CHI3L1 levels and CPA (r = 0.351, P < 0.001) (Fig. 3a) , and between CHI3L1 levels and LSM (r = 0.412, P < 0.001) (Fig. 3b) . The ROC curve analysis revealed that the performance of CHI3L1 in identifying significant liver fibrosis (Ishak ≥F2) was superior to APRI and FIB-4 with a cut-off value of 60.9 ng/mL (area under the curve = 0.86) (Fig. S3 ).
Post-treatment CHI3L1 levels also were correlated with CPA and LSM After 78 weeks treatment, CPA decreased from baseline 3.39% to post-treatment 2.42% (P < 0.001) (Fig. 4a) , and the LSM from 10.3kpa to 6.3 kPa (P < 0.001) (Fig. 4b ). There were positive correlations between serum CHI3L1 levels and CPA (r = 0.293, P = 0.001) (Fig. 4c) , and between serum CHI3L1 levels and LSM (r = 0.443, P < 0.001) (Fig. 4d) .
Changes in CHI3L1 levels after treatment positively correlated with changes in CPA and LSM We found there were positive correlations between the changes in CHI3L1 levels and the changes in CPA and LSM pre-and post-treatment. The correlation coefficient was 0.366 between CHI3L1 and CPA, and 0.438 between CHI3L1 and LSM. Both correlations had statistical significance (P < 0.001) (Fig. 5 ).
Factors associated with CHI3L1 levels using multivariate regression analysis
The multivariate linear regression analysis showed that the factors associated with pretreatment CHI3L1 levels were fibrosis severity assessed by CPA measurement and inflammatory score. There were positive correlations between CPA, inflammatory score, and CHI3L1 levels (β = 5.450, P = 0.019; β = 2.864, P = 0.047) ( Table 2 ). In the multivariate analysis, the factors contributing to post-treatment CHI3L1 levels were treatment drugs and CPA values. The 
CPA values had positive correlation with post-treatment CHI3L1 levels (β = 7.460, P = 0.023). Some patients received ETV and pegylated interferon (peg-IFN) combination treatment (n = 19). The CHI3L1 levels in patients who received the combination treatment were higher than in those treated with ETV alone (n = 112) (74.2 vs. 61.5 ng/mL).
DISCUSSION
I N THIS STUDY, we found that serum CHI3L1 levels not only had positive correlations with CPA and LSM before treatment, they also had correlations at 78-week posttreatment. More importantly, the changes in CHI3L1 levels after treatment also were correlated with the changes in , and the CHI3L1 levels also decreased significantly (P < 0.001) (c). **P < 0.001.
CPA and LSM. Multivariate linear regression analyses further indicated that there were positive correlations between CPA value and CHI3L1 level pre-and posttreatment. Our results suggested that serum CHI3L1 would be used as a potential surrogate marker for monitoring fibrosis change during treatment. Also known as YKL-40, CHI3L1 belongs to the chitinase family but lacks chitinolytic activity, which highly enriches in the liver. 8, 9 It was reported to act as a growth factor for fibroblasts and to be involved in matrix remodeling. 10, 11 Serum CHI3L1 levels were reported to be associated with the severity of liver fibrosis caused by non-alcoholic fatty liver disease, schistosomiasis, hepatitis C virus, and HBV.
12-15 Interestingly, we found that CHI3L1 levels declined in CHB patients with liver fibrosis regression after antiviral therapy, whereas it had been reported that 
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CHI3L1 levels were significantly increased in chronic hepatitis C patients with risk of disease progression. 16, 17 To obtain further histological information, we applied the automatic CPA measurement as the gold standard, instead of the conventional histological scoring algorithm, in evaluating fibrosis changes. [18] [19] [20] [21] [22] This new technology enables CPA measurement to be carried out on unstained liver sections automatically using a SHG/TPEF technology-based microscope. It could maximize the reproducibility by avoiding staining procedures and operator variances. 6, 7 Collagen proportionate area, the quantitative fibrosis measurement, was more sensitive than the semiquantitative Ishak scoring system in evaluating fibrosis change after treatment. Our recent study found that fibrosis reversal had taken place, as assessed by the new CPA classification, in many patients who were assessed as having post-treatment non-regressive fibrosis measured by Ishak score. 23 According to the new assessment, we found that the levels of CPA and CH3L1 were lower in patients with regressive liver fibrosis than that in progressive fibrosis patients (Table S2) , and the difference in CPA had statistical significance.
We also compared serum CHI3L1 levels with LSM, which is widely used as a non-invasive method for assessing liver fibrosis. [24] [25] [26] Previous studies have shown that the LSM declined significantly in CHB patients after antiviral treatments. However, whether dynamic changes of LSM could be used to monitor the changes in liver fibrosis remained controversial. [27] [28] [29] We found that changes in CHI3L1 levels were correlated with the changes in LSM, suggesting both of them could be used for monitoring dynamic changes of liver fibrosis in CHB patients during antiviral therapy.
There were some confounding factors that influenced the CHI3L1 in evaluating liver fibrosis. Liver necroinflammation was an important influencing factor on the CHI3L1, especially at baseline. However, ALT and AST were not related with CHI3L1 in this study; the reason might be that many patients received traditional Chinese medicines before antiviral treatment that could decrease aminotransferase. The treatment was an important confounding factor influencing the posttreatment CHI3L1 levels. Although the CHI3L1 levels declined in both the ETV and peg-IFN combination treatment group (from 82.7 to 74.2 ng/mL) and the ETV monotherapy group (from 97.8 to 61.5 ng/mL), the reduction from pre-to post-treatment was greater in the monotherapy group than that in the combination treatment group (26.5 vs. 8.0 ng/mL).
There were several limitations in the present study. The number of patients was limited. However, the sample size of our study was large enough to undertake the statistical analyses, and the power was sufficient. Additionally, changes in histological measurements might lag behind the biochemical changes, thus introducing bias for the comparisons.
In conclusion, we found that changes in serum CHI3L1 levels were correlated with changes in quantitative assessments of liver fibrosis (CPA and LSM) among CHB patients who received antiviral therapy. It indicated that CHI3L1 change could be a potentially useful, non-invasive method to monitor fibrosis changes. Figure S1 Liver tissue collagen proportionate area (CPA) measurement using second-harmonic generation (SHG)/ two-photon-excited fluorescence (TPEF) microscopy. Collagen and hepatocyte morphology were detected by SHG and TPEF signals, denoted in green and red, respectively. CPA was the ratio (percentage) of area of fibrillar collagen to its corresponding liver tissue. Figure S2 Chitinase 3-like 1 (CHI3L1) levels in patients with different liver fibrosis stages (1-6, Ishak scores) at baseline. CHI3L1 levels increased with fibrosis stages and there were significant differences among patients with mild fibrosis (1), significant fibrosis (2/3), severe fibrosis (4), and cirrhosis (5/6). *P < 0.05; **P < 0.01. Figure S3 Areas under the receiver operating characteristic curves of chitinase 3-like 1 (CHI3L1), aspartate aminotransferase to platelet ratio index (APRI), Fibrosis-4 (FIB-4) index, and platelets were: 0.86, 0.78, 0.51, and 0.34, respectively, for diagnosing pre-treatment Ishak score ≥F2; 0.65, 0.59, 0.62, and 0.33, respectively, for Ishak ≥F3; 0.70, 072, 0.74, and 0.21, respectively, for Ishak ≥F4; and 0.67, 0.69, 0.68, and 0.23, respectively, for Ishak ≥F5. CHI3L1 showed significantly better performance for diagnosis of Ishak ≥F2 than other markers. Cut-offs for diagnosing ≥F2, ≥F3, ≥F4, and ≥F5 were 60.9 ng/mL (sensitivity, 82%; specificity, 83%), 73.8 ng/mL (sensitivity, 53%; specificity, 70%), 91.9 ng/mL (sensitivity, 69%; specificity, 67%), and 106.9 ng/mL (sensitivity, 61%, specificity, 70%), respectively. Table S1 Characteristics of patients with chronic hepatitis B classified as biochemical and virologic responders or non-responders at pre-and post-treatment with entecavir Table S2 Characteristics of markers according to the new fibrosis activity classification of "P-I-R" (Progressive -Indeterminate -Regressive) pre-and post-treatment with antivirals
ACKNOWLEDGMENTS
